Aspect Biosystems partners with Merck, Gsk, And Mcgill University to enable development of immuno-oncology therapeutics

Aspect Biosystems partners with Merck, Gsk, And Mcgill University to enable development of immuno-oncology therapeutics

2019-06-05

Aspect Biosystems is proud to announce a collaboration with Merck, GSK, and McGill University’s Goodman Cancer Research Centre. This $2.2M project is made possible by contributions from CQDM, the Canadian Cancer Society, Merck, GSK, Aspect Biosystems, and McGill University. These contributions underscore their commitment to driving innovation that will unlock the discovery of novel therapeutic targets and the development of immuno-oncology therapeutics. Read More >>